Epithelial cancers are defined by a tumor-specific distribution of chromosomal aneuploidies that are maintained when cells metastasize and are conserved in cell lines derived from primary tumors.
| I N TR ODU C TI ON
Epithelial cancers are defined by a specific distribution of chromosomal aneuploidies, that is, chromosome numbers that are not the multiple of the diploid complement. [1] [2] [3] The resulting genomic imbalances are tumor specific, are maintained when cells metastasize, and are conserved in cell lines derived from primary tumors. 4 For instance, trisomy of chromosome 7 in colorectal adenomas is one of the earliest chromosomal alterations observed in the development of sporadic colorectal carcinomas (CRCs). 5, 6 During CRC carcinogenesis, the gain of chromosome 7 is later complemented by copy number increases of chromosomes and chromosome arms 13, 8q, and 20, and losses of 4 and 18. 7 These imbalances in CRC result in ploidy-driven transcriptional deregulation of genes residing on the aneuploid chromosomes and are also found in other tumor entities. [8] [9] [10] [11] The strong selection for the maintenance of chromosomal aneuploidies very convincingly suggests a functional relevance as drivers of tumorigenesis. However, it remains unknown to which extent, and how, aneuploidy-dependent transcriptional deregulation contributes to cellular transformation, in particular at early stages of tumorigenesis when these aberrations emerge, and to which extent they are required for the maintenance of the malignant phenotype.
The histone deacetylase inhibitor (HDACi) trichostatin A (TSA) is a well-known anticancer agent that leads to large-scale gene-expression changes and exerts its effect by altering the transcriptional regulation of specific cancer-related genes. 12 were used and detection was performed by chemiluminescence using SuperSignal West Pico (Thermo Fisher Scientific).
| Gene-expression microarrays
Total RNA was isolated from the cells using the RNeasy Mini Kit (Qiagen, Hilden, Germany) and RNA integrity (RIN) was assessed with an RNA 6000 Nano LabChip Kit using a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). Only samples with a RIN number >8.0 were included, and five replicates per condition were used. One microgram of RNA from each cell line was amplified and labeled using the Quick Amp Labeling Kit, one-color (Agilent) and subsequently hybridized on Human GE 4x44K v2 Microarrays (Agilent) according to the manufacturer's protocol version 6.5. Slides were scanned with a microarray scanner G2565BA (Agilent). Images were analyzed and data were quality controlled using Feature Extraction software version 10.7.1.1 (Agilent). The microarray specifications and derived data are accessible through National Center for Biotechnology Information (NCBI) Gene
Expression Omnibus (GEO) accession number GSE100705.
| Data analysis
Array data were log 2 -transformed, normalized, and corrected for multiple testing. Significance analysis for microarrays (SAM) software was used for the identification of differences in gene expression due to treatment with TSA at a false discovery rate (FDR) of 5%, with minimum fold changes of 3.0. For the identification of differently expressed gene due to the introduction of an additional copy of chromosome 7 in DLD-1 cells, a t test was used with P value <0.05 and a minimum fold change of 1.5.
IPA software (v01-10, Ingenuity, Mountain View, CA) was used to assess the involvement of significantly differentially expressed genes in known pathways. The IPA pathways were listed by significance rank order, that is, with the pathways having a lower likelihood that the generation of the pathways was serendipitous listed on top. Cutoff values for significant meaningful pathways was set at P value <0.05
and false discovery rate (FDR) < 0.05.
| RE S U L TS

| TSA treatment reduces viability of CRC cell lines
The treatment effect of different TSA concentrations on the viability of the diploid CRC cell line DLD-1, the cell line DLD-1 1 7 into which we introduced an extra copy of chromosome 7, and the aneuploid cell line SW480, which carried gains of chromosome 7, was analyzed. The viability of the cell lines was reduced between 30% and 60% for all concentrations tested (40-1,000 nM) (Fig. 1A) . The effect of TSA on the action of histone deacetylases was assessed by Western blot analysis using antibodies against acetylated histones H3 and H4 (Fig. 1B) . Acetylation of both histones was increased in a dose-dependent manner and can be clearly observed starting at 120 nM in all cell lines. The effect of TSA on apoptosis was also assessed by Western blot analysis using antibodies against cleaved PARP (Fig. 1C) . Cleavage of PARP was increased in a dose-dependent manner and can be clearly observed starting at 320 nM in all cell lines. As 160 nM TSA represented the concentration that maximally inhibited histone deacetylases, while at the same time having a minimal effect on the induction of apoptosis, this concentration was used to treat the cells for gene-expression profiling.
3.2 | Effect of TSA on whole chromosome average gene-expression levels (Fig. 4A ). This highlights that TSA asserts a preferential downregulating effect on the transcriptome of chromosome 7 when an additional copy of chromosome 7 is present, compared to its downregulating effect on the other chromosomes.
| Potential therapeutic targets
To identify genes located on chromosome 7 potentially having a beneficial effect on CRC tumor cell viability, the gene list of upregulated genes in DLD-1 1 7 versus DLD-1 was compared to the gene list of downregulated genes in DLD-1 1 7 1 TSA versus DLD-1 1 7. These gene lists only had three genes in common: PON2, ASB4, and ZNF273.
Out of these genes, ASB4 was also among the genes that were downregulated in SW480 by TSA treatment.
To identify whether the genes downregulated by TSA treatment in cells with an additional copy of chromosome 7 clustered together in gene signaling pathways, we used ingenuity pathway analysis (IPA).
The following pathways were significantly downregulated in aneuploid DLD-1 1 7 and SW480 cells, but not in diploid DLD-1 cells: "Role of CHK proteins in cell cycle checkpoint control," "Estrogen-mediated Sphase entry," "Cyclins and cell cycle regulation," "Cell cycle: G1/S checkpoint regulation," and "Molecular mechanisms of cancer." The "Role of CHK proteins in cell cycle checkpoint control" and "Molecular mechanisms of cancer" pathways contained genes located on chromosome 7: RFC2, PRKAR1B, SMO, and CDK6. We conclude that the exposure of cells with a chromosomal aneuploidy to TSA preferentially downregulates the expression levels of the genes located on the aneuploid chromosome and that these genes cluster together in gene signaling pathways mainly involved in cell-cycle regulation.
| D I SCUSSION
Using gene expression profiling, we have analyzed how HDAC inhibition by TSA modulated the transcriptome in diploid and aneuploid colorectal cell lines with additional copies of chromosome 7, a genomic imbalance often observed in primary CRC. 5, 6 Treatment with TSA reduced the viability of DLD-1, DLD-1 1 7, and SW480 by 30%-60%, although genome-wide transcriptional deregulation is observed as well. 9 As it is unknown to which extent this aneuploidy-dependent transcriptional deregulation contributes to tumorigenesis, we studied whether TSA, a compound that induces cellular differentiation and has antitumor activity in cancer cell lines, could reverse the aneuploidydependent gene expression changes. Previously, it has been described that despite the broad effect of TSA on the whole genome, it also has some minor site-specific action on certain chromosome regions, as it is able to selectively inhibit/stimulate gene expression via different promotors which may be connected with locus-specific acetylation patterns and chromatin structure. [17] [18] [19] Especially, genes that are highly expressed, including amplified genes, have been described to be preferentially repressed by TSA. 20 As gain of chromosome 7 is so crucial for CRC tumorigenesis, it most likely harbors important oncogenes and we expected that treatment with TSA would be able to selectively reverse overexpression of these oncogenes. Indeed, we found that TSA preferentially downregulated the gene expression on chromosome 7 in DLD- downregulation of ASB4 in SW480. PON2 is a member of the family of paraoxonases that localize to the endoplasmatic reticulum and to the nucleus; it has an antiapoptotic function. 21, 22 PON2 is upregulated in various tumor types, including endometrial, liver, kidney, bladder, and lymphoid cancers. 23, 24 Of special interest is the fact that PON2 expression has been described to be regulated through the Wnt/GSK3b/ b-catenin pathway and that its expression was correlated with radiotherapy resistance in oral squamous cell carcinoma patients. 25 Resistance to chemoradiotherapy (CRT) occurs in 30% of the patients with rectal cancers that undergo treatment. 26 CRC carcinogenesis is associated with critical alterations in Wnt/b-catenin signaling, 27 and it has been demonstrated that preoperative CRT for locally advanced rectal cancer induced a significant increase in nuclear b-catenin expression in 49% of the patients. 28 This increase in nuclear b-catenin expression was correlated with poor survival. 28 It is already known that silencing of the Wnt pathway transcription factor TCF7L2 results in increased sensitivity to chemoradiation of CRC cell lines. 29 Based on our study results, it would be interesting to investigate whether silencing of PON2 could reverse CRT resistance in CRC, which might improve the prognosis of CRC patients. Also, the exact function of ASB4 in CRC should be studied in more detail. Currently not much is known about ASB4 with regard to its role in tumorigenesis, except for the fact that it is overexpressed in hepatocellular carcinoma (HCC) cell lines and that suppression of ASB4 inhibited migratory and invasive properties of HCC cells. 30 ASB4 is an especially interesting gene for future studies,
as it was commonly downregulated in DLD-1 1 7 which harbors PIK3CA mutations and in SW480 bearing the wild-type PIK3CA, underlining that this gene might offer a therapeutic target in CRCs with and without PIK3CA mutations. 31 Finally, we have observed that the gene-signaling pathways that were commonly downregulated by TSA treatment in both DLD-1 1 7
and SW480 cells were mainly involved in cell-cycle regulation. Genes from these significantly downregulated pathways located on chromosome 7 were RFC2, PRKAR1B, SMO, and CDK6. Inhibition of CDK6 by PD-0332991-a selective CDK4/6 inhibitor that has been approved by the FDA for treatment of breast cancer-has already been described to induce G1 arrest in cells of several CRC cell lines, and has been suggested to be a novel therapeutic agent for treatment of CRC. 32 The inhibition of SMO protein expression has also been described to suppress proliferation of CRC cells. 33 However, the potential oncogenic roles of RFC2 and PRKAR1B remain unclear, and their potential as therapeutic targets in CRC should be further investigated.
